Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Stay with the program"? What's that supposed to mean? So are you saying Alex Denner (Sarissa) involvement had nothing to do with a -65% drop in the share price while the Bio index rose +65%. How is that "squirming past the facts? Do I need to remind you PRICE IS KING... PRICE IS FACT!
Quit trying to bamboozle people into thinking you know what you’re talking about?
le pain et le loueil d'olive is optional It is one of the most beautiful towns I have been in and would recommend to anyone. Very close to Spain with just the Pyrenees to cross. Nice local vin yards.
Wow that’s as close to Spain as you can get. Never been to an anchovie bar - do they have bread and butter to go with that?
Surely, they should recognize the value of EPA.
Can only hope they nail this guy and other like him
https://finance.yahoo.com/news/us-accuses-short-seller-andrew-125959087.html
Come on France! Pull your Head Out!
i spent the last two weeks in the south of France near Collioure and they have Bar À Anchois - Anchoive Bars - i was in heaven, white wine and Anchovies- its the EPA stupid
But on a serious matter does Amarin have to overcome the Anchovies lobby to get reimbursement approval in France? O la la...
Along with suggesting Icosapent Ethyl to those patients they should also suggest to the French govt agency in charge to hurry up with their reimbursement for Vazkepa.
But like you say, slow but sure the data is mounting, and they eventually have to succumb.
Nice find Sleven............. drip drip drip of good positive affirmation information
About time. Hope others get indicted as well.
https://www.wsj.com/finance/stocks/u-s-accuses-prominent-short-seller-andrew-left-of-fraud-0161e42f
Looks like VASCEPA®/VAZKEPA® safety profile in the Real World (RW) is significantly better than reported in the REDUCE-IT RCT & the labels in the USA & Europe. Check out these AE rate comparisons. VASCEPA®/VAZKEPA® = Safe & Effective.#IPE @SABOURETCardio @DLBHATTMD pic.twitter.com/QNelYdvOGU
— Mike Everts (@GeoWizz_) July 26, 2024
I like how you squirm past the facts. Your question to Irish was about Alex Denner (Sarissa) involvement and who controlled Amarin’s destiny when the share price was last time @ $4.77?
So, what’s happened since then is apparently in your perspective all Alex Denner & Sarissa’s fault? Really? Stay with the program. Quit trying to bamboozle people into thinking you know what you’re talking about?
AMRN has traded more in line with the small-cap biotech index, not the XBI or even the Russell 2000 index. I picked AMRN as my top pick in a IHub contest of 10 savvy LT picks that began in early May and will end in late April or May 2025. My entry point for AMRN in the contest is $0.688. Other picks with entry values are CDMO= $7.14, ATNM= $7.40, AVXL= $4.22, MAGS= $45.11, MNMD= $7.21, NVDL= $69.55, NWBO= $0.428, VKTX= $53.01 and XERS= $2.25. None of those picks can be traded on a short term basis; all are LTBuyHOLD. Contestants hope that each of their picks will have a higher share price at contest end next year, with buyouts/M and A activity at multiples of entry values a possibility.
I'm tastytheelf by the way. MRM made me change my handle.
If they are maintaining a $50mm buyback (we'll have to see what they say in the Q2 earnings call), and they want to do it like grown-up companies do, then they'd stretch it out over like 6 months to a year, and there would be some opportunism to it.
You'd be looking at 250k to 500k shares per trading day I would think. Right now that would distort the market and drive the price up.
It should be! It isn't some kind of Frankenstein gene-altering, cancer-causing chemical -- it's a natural extract!
Nice find Dogn, thank you.
Efficacy - CHECK!
MO Placebo Issue Debunked - CHECK!
AFib Risk Debunked - CHECK!
The Absolute Risk of these two AE’s in trial vs. placebo were very low to begin with. It appears that in the RW the risk is nearly zero.
V is possibly the safest of any CV drug while delivering efficacy >= statins and cost effectiveness 3-5X than PCSK-9’s.
Our Friend, Dr John Nelson once again brilliantly showing the consistency of REDUCE-IT data and how safe VASCEPA/VAZKEPA is in the Real World. All the negative hype about bleeding and Afib with IPE is laid to rest.
Great positive example of the V safety profile. The real world data shows far less adverse events than the Reduce-It study results.
Journal of Clinical Lipidology
Volume 18, Issue 4, Supplement, July–August 2024, Page e574
Comparison of Package Insert versus Real World Safety Data from Branded Icosapent Ethyl Users: A Select Analysis Utilizing MarketScan Data.
https://www.sciencedirect.com/science/article/abs/pii/S1933287424001594
Conclusions
RWD demonstrated trends in the frequency of IPE-labeled AEs that are consistent with, but 3-5x lower than, trial and labeling data. Potential reasons for consistently lower AE rates in RWD compared with trial data may be related to differences in how AEs are assessed and documented in the real world vs. in trials.
October 25, 2021 Amarin closed at 4.77. Who was running the company? Who was in the Whitehouse? Screwing with the interest rates and giving $Billions to Ukraine? We were neck deep with Covid as well. Perfect storm?
FlyFishingStocks
Still think the buy back is in progress ? Total volume today less then 400,000 shares traded TIA
Michael
FFS, should we add more, hold, or sell before the Q next Wednesday. What does the chart say? Thanks in advance.
October 25, 2021 Amarin closed at 4.77. Who was running the company? Who was in the Whitehouse? Screwing with the interest rates and giving $Billions to Ukraine? We were neck deep with Covid as well. Perfect storm?
I’ll answer for Irish; it’s called who resides in the Whitehouse!!! And who was at the helm 2 years ago when the stock cratered.
Jesus man get a life.
Still waiting mr. denial for your opinion as to why/how the stock price plunged from $4.50 to .65 spanning the time of Denner's involvement to date.
Do you not have an answer?
JR, Have to agree with you here. Denner and Sarissa 'likely have a lot of influence' on how Amarin is run - but as you said 'Denner is NOT on the board'.
And Hedge Funds works often in 'teams' - no way anyone can say that Sarissa is (not though partners) shorting Amarin - if they valuate that to be the best short term way to do business / make money.
-------------------------
And I am with you all the way - that Sarissa and Denner have 'big long term plans' for Amarin.
I like $10- 15 better than $5. BO announcement will be there some day - 2025 - 26 - not unlikely, if besides UK - a couple of other big countries in EU and possibly China - will start to create noticeable revenue ✌️
DAR, The case I posted looks like it might be Canadian. If so, it doesn't represent a precedent we can use.
CAFC has already ruled on the appeal.
Sleven,
NS, thanks for the link. So based upon this case, it would appear to me that no only is Hikma infringing (case ongoing), but the other generics could be found guilty of infringement against Amarin. The skinny label is certainly be infringed upon in the CVD area regardless of the fault of doctors, insurers or PBMs. Amarin has to gain traction on some of these legal cases as precedent.
I don't recall the date for the Hikma / Amarin CAFC official response. Is that August 13?
Lowest volume day that I can remember..... will be interesting to see what happens in the next 8 mins
JRoon, I will find and post the actual ruling later. This infringement case is almost identical to the situation that Amarin is in. The generic companies have a mono therapy label. Our label involves combination therapy. Ths is the same situation as the case I posted. Apotex was found guilty of inducing infringement because the majority of patients being treated were given combination therapy.
Sleven,
Hey mister come afterwards
Laws are laws and board directors are well aware of where Bernie Madoff ended up...of course companies short but Sarissa Denner in this case cannot. You know zero about what I have held or not held, you of 0000's of posts on 1 stock...
Why would you only discuss one stock if you actually knew trading...with graphs handles tails of yours but only 1 stock..
We know what you are ..
Good find, Sleven.
The last paragraph was interesting:
This case suggests that, in order to succeed in “skinny label” cases, a generic manufacturer may need to overcome established prescribing practices, which may be influenced not only by the patentee’s label but its market tenure as well.
Hey thur mr. denial. Let's hear your opinion as to why/how the stock price plunged from $4.50 to .65 spanning the time of Denner's involvement to date. Be sure to lace it with facts (as you demand of other posters).
Based on my opinion/strategy (which I'm sure you are aware of), I am shocked you have held your shares clear down to the bottom - especially since you proclaim to be so smart. You have chosen to see the AMRN investment completely opposite to my thinking, but that's your opinion. Differing opinions are the very ingredients that make up a 'market' composed of buyers and sellers. That's why companies like Sarissa can exploit FOMO retail and become filthy wealthy.
Don't overdose on your grumpy pills.
Kiwi, no disclosure of buyback yet. And no filings. So "officially", no shares purchased yet. But there's still the possibility that Cantor is buying and accumulating in their own account, and have not transferred shares to Amarin yet. I imagine Amarin will need to explain where they are in the process at the CC next week.
As far as shorting, you are correct, board member cannot short. However, this does not prohibit Sarissa (the investment firm) from shorting (as they stated in their proxy) until they reach 10% ownership. It also does not prevent any "partners" from shorting.
But they would not state in their SEC filing that they could potentially short the stock, if that were illegal.
RMB My quick take is that most companies prohibit members of the BOD from shorting their Co's stock ...for reasons mentioned by others here .
However there maybe loop holes that Denner / Sarissa are using to short if they wanted to....and they have disclosed as such .
What I think is more significant is has AMRN disclosed any buy back purchases yet ?
I've been on vacation so haven't followed the board much lately .
Any news on the share buyback ?
Kiwi
Yeah, I was just commenting on the thread in general.
Rainy
Just go away
Soft sly bashing
Anyone connected in any way with Sarissa / Dinner would be put away for years for that.
Consistently you suggest the most idiotic unbelievably stupid ideas as if you had intellect.
To school boy now
I wasn’t speaking to any of those questions or points, only trying clear up any possible confusion as to whether the 10% applied to directors - in any public company.
Anyone on a BoD that shorts the stock of the company they are charged with as a fiduciary should be fired immediately, regardless of legality. I have never heard of anyone on a BoD do that.
Who said anyone on the board was doing this directly?
Also, Alex Denner is not on the Board.
Rose
Yes exactly
BOD must declare irrespective of the size of their holdings. It would plainly be insider trading as they would have knowledge before anyone else.
Kiwi, not sure if it was because I knew 3 languages before starting kindergarten, but I seemed to have a bit of difficulty with comprehension.
So maybe I am not clear on this, but the SEC rule you posted, I understand to mean that the 10% only applies to shareholders. Otherwise, executives or directors (BOD) would have to declare before shorting the way I comprehend it, right?
Section 16 of the Securities Exchange Act of 1934:
Under Section 16, executive officers, directors, and significant shareholders (those owning more than 10% of the company's stock) must file public reports disclosing their holdings and transactions in the company's equity securities. Transactions must be reported within two business days using Form 4
Thank you for belying the bipolar egomaniacal cardiologist stereotype.
Ruin
Nope
Sarissa as an investment entity may short declare able shareholdings which they state in their company information. Once they take up board positions they become insiders and as such if they were to even intend to short or go long they must declare that intent in advance.
Ruiny back to school boy.
Readers may want to look at/skim read a willful infringement, damages case/opinion released Tuesday this past week in the E.D Texas after entry of redactions:
NETLIST v. SAMSUNG et al
Post # 24778 on the NETLIST IHub board.
About $500,000,000 damages found by a jury. Different facts and patents of course, but note that Hikma(like Samsung) does continue to sell product after filing of Amarin complaint. Will Hatch Waxman make a difference? Reread the recent CAFC opinion in Amarin v. Hikma.
Followers
|
1105
|
Posters
|
|
Posts (Today)
|
21
|
Posts (Total)
|
427195
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators ziploc_1 zmanindc golf stud Number sleven |
AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote
Y! Finance AMRN Landing Page
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |